Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY
Details : Velsipity (etrasimod), an FDA approved oral, once-daily, selective S1P receptor modulator. It is being evaluated for treatment of adults with moderately to severely active ulcerative colitis.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2024
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Abivax Presents Preclinical Data for UC Therapy with Obefazimod and Etrasimod
Details : Abivax is actively conducting preclinical studies ABX-464 (obefazimod) in combination with Etrasimod for treating Inflammatory Bowel Disease (IBD) in the Mouse Model.
Product Name : ABX-464
Product Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2024
Lead Product(s) : Obefazimod,Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
Details : Velsipity (etrasimod) is an FDA-approved oral S1P receptor modulator, with its NDA accepted in Macau for adults with moderately to severely active ulcerative colitis.
Product Name : Velsipity
Product Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2024
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Velsipity (etrasimod) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. It is approved for the treatment of patients with moderately to severely active ulcerative coliti...
Product Name : Velsipity
Product Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2023
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, is approved by the FDA for adults with moderately to severely active ulcerative colitis (UC).
Product Name : Velsipity
Product Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2023
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : APD334 (etrasimod) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. It is being investigated for the treatment of moderate-severe active ul...
Product Name : APD334
Product Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2023
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Everest Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflamma...
Product Name : APD334
Product Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Everest Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : APD334 (Etrasimod) is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5.
Product Name : APD334
Product Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5.
Product Name : APD334
Product Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator being investigated for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and ...
Product Name : APD334
Product Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2022
Lead Product(s) : Etrasimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable